White Paper

Pharma R&D Annual Review 2023

Source: Citeline

By Ian Lloyd, Senior Director, Pharmaprojects at Citeline

GettyImages-1271408632 book brain

For over three decades, Senior Director of Pharmaprojects at Citeline, Ian Lloyd, has been reviewing annual trends and evolutions in pharmaceutical research and development. In the 31st edition, Lloyd recently examined the state of play at the start of 2023 by taking into account the pipeline by company, therapeutic area, disease, target, and drug type, using data from primarily Pharmaprojects, part of the Citeline suite of products, which has been tracking global drug development since 1980.

Presented in a literary theme to highlight points, draw analogies, and add a little character into what could otherwise be a rather lengthy narrative through a collection of statistics, charts, and tables, Lloyd tells the story of pharma R&D as it is today: an epic tale, with a rich cast of characters and a global scope, and several unexpected plot twists.

“Storytelling is as old as humanity itself, and fiction has always been used as a proxy to help us to understand the real world,” writes Lloyd. “The best literature enlightens, thrills, amuses, and engages the reader. I’m certainly no Shakespeare, but I hope that my words will throw some light on the current state of the pharmaceutical industry, in the same way that a great novel does on the human condition.”

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader